Search

Displaying results 2241 - 2250 of 9313 in total
  1. Drug

    Venetoclax

    go.drugbank.com/drugs/DB11581
    ApprovedInvestigational

    Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process [A18565], [A18566]. … Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries [A40022].

  2. Drug

    Interferon gamma-1b

    go.drugbank.com/drugs/DB00033
    ApprovedInvestigational

    Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. … The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b.

  3. Drug

    Japanese Encephalitis Virus Vaccine Inactivated

    go.drugbank.com/drugs/DB19294
    ApprovedWithdrawn

    Synonyms: JE-VAXMixtures: Je-vax 1 Dose
  4. Drug

    BNT162B2 Omicron (LP.8.1)

    go.drugbank.com/drugs/DB23337
    Approved

    [L53723] It encodes the spike protein from the Omicron LP.8.1 subvariant of SARS-CoV-2.[L53723] The 2025-2026 formulation of Pfizer-BioNTech's Comirnaty was approved by the US FDA in August 2025. … BNT162B2 Omicron (LP.8.1) is the active ingredient in the 2025-2026 formulation of Pfizer and BioNTech's Comirnaty mRNA vaccine for COVID-19.

  5. Drug

    Somapacitan

    go.drugbank.com/drugs/DB15093
    ApprovedInvestigational

    [A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. … Somapacitan, also known as NNC0195-0092,[A219136] is a growth hormone analog indicated to treat adults with growth hormone deficiency.

  6. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    [L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections … The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).

  7. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … [suvorexant]) act to counteract inappropriate wakefulness.

  8. Drug

    Cinoxate

    go.drugbank.com/drugs/DB15467
    ApprovedWithdrawn

    Mixtures: Le Stick A Levres Onybel
  9. Drug

    Cilastatin

    go.drugbank.com/drugs/DB01597
    ApprovedInvestigational

    The first combination product containing both drugs was approved by the FDA in November of 1985 under the trade name Primaxin, marketed by Merck & Co. … Since the antibiotic, [imipenem], is one such antibiotic that is hydrolyzed by dehydropeptidase, cilastatin is used in combination with imipenem to prevent its metabolism.

    Mixtures: IMIPENEM E CILASTATINA SUN, IMIPENEM E CILASTATINA SUN
  10. Drug

    Vorapaxar

    go.drugbank.com/drugs/DB09030
    Approved

    Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history

    Synonyms: [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-Fluorophényl)-2-pyridinyl]vinyl}-1-méthyl-3-oxododécahydronaphto[2,3-c]furan-6-yl]carbamate d'éthyle, Carbamic acid, [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)-2- pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester